| Dunshee, Curtis |
NCT04691804 / 2020-006063-28: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer |
|
|
| Active, not recruiting | 3 | 496 | Europe, US, RoW | Fuzuloparib , Abiraterone acetate and Prednisone, SHR3162, Fuzuloparib Placebo， Abiraterone acetate and Prednisone | Jiangsu HengRui Medicine Co., Ltd. | Metastatic Castration-Resistant Prostate Cancer (mCRPC) | 12/26 | 12/26 | | |
NCT04060394: Dose-Escalation and Efficacy Study of LAE001/Prednisone Plus Afuresertib Patients With m-CRPC |
|
|
| Completed | 1/2 | 49 | US, RoW | Phase I and Phase II: LAE001/prednisone + afuresertib, Phase II: Afuresertib | Laekna Limited | Metastatic Castration-resistant Prostate Cancer | 12/23 | 03/24 | | |
| Kalota, Susan |
VERACITY, NCT04844749: Efficacy Evaluation of VERU-111 for mCRPC in Patients Who Have Failed at Least One Androgen Receptor Targeting Agent |
|
|
| Terminated | 3 | 105 | US | VERU-111, Sabizabulin, Enzalutamide, Abiraterone, XTANDI, Zytiga | Veru Inc. | Metastatic Castration-resistant Prostate Cancer, Androgen Resistant Prostatic Cancer | 05/23 | 05/23 | | |
| Recruiting | 3 | 96 | Europe, US | AMDC-USR (iltamiocel), Placebo | Cook MyoSite | Stress Urinary Incontinence | 01/25 | 02/26 | | |
| Terminated | 1b/2 | 24 | US | VERU-100 | Veru Inc. | Advanced Prostate Adenocarcinoma | 01/23 | 01/23 | | |
NCT05710848: A Study of STM-416 Administered to Patients Undergoing TURBT for Recurrent Bladder Cancer |
|
|
| Recruiting | 1/2 | 75 | US | STM-416 | SURGE Therapeutics | Non-muscle-invasive Bladder Cancer | 12/25 | 12/25 | | |
LEGEND study, NCT04752722: LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve |
|
|
| Recruiting | 1/2 | 222 | Canada, US | EG-70 (phase 1), Phase 1, EG-70 (phase 2), Phase 2 | enGene, Inc. | Superficial Bladder Cancer, Non-muscle Invasive Bladder Cancer With Carcinoma in Situ | 06/25 | 05/27 | | |
NCT04629170: Safety and Tolerability of SYNB8802 in Healthy Adult Volunteers and Adult Subjects With Enteric Hyperoxaluria |
|
|
| Completed | 1 | 77 | US | SYNB8802, Placebo | Synlogic | Healthy, Enteric Hyperoxaluria | 01/23 | 01/23 | | |
| Recruiting | N/A | 390 | US | Active treatment, Sham | Viveve Inc. | Urinary Incontinence, Stress | 12/22 | 12/22 | | |
